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Aim To investigate the ability of two standard quality of life 
(QOL) questionnaires – The Short Form (36-item) Health 
Survey (SF-36) and The European Organisation for Research 
and Treatment of Cancer Quality of Life Questionnaire-
Core 30 (EORTC QLQ C30) to evaluate QOL in patients with 
chronic graft-vs-host disease (cGVHD) graded according to 
National Institutes of Health (NIH) consensus criteria.
Methods In this cross-sectional study, QOL was assessed 
in patients who underwent allogeneic stem cell transplan-
tation (allo-SCT) at the University Hospital Centre Zagreb 
and were alive and in complete remission for more than 
one year after allo-SCT.
Results The study included 58 patients, 38 patients with 
cGVHD and 20 controls, patients without cGVHD. Patients 
with cGVHD scored according to the NIH criteria had sig-
nificantly lower scores of global health status and lower 
QOL on all SF-36 subscales and most of QLQ C30 function-
al subscales (P < 0.050 for all comparisons). Furthermore, 
patients with active cGVHD had significantly lower QOL 
scores than patients with inactive cGVHD, and this differ-
ence was most evident in physical functioning subscale of 
SF-36 (P = 0.0007) and social functioning subscale of QLQ 
C30 (P = 0.009).
Conclusion cGVHD scored according to the NIH criteria 
is correlated with patient-reported QOL, particularly in the 
physical domains as detected by SF-36. QLQ C30 question-
naire adds more information on social functioning and 
should be used as a valuable tool in the evaluation of so-
cial domains in cGVHD patients.
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Although it is potentially lifesaving for a variety of hemato-
logical malignant and non-malignant disorders, allogeneic 
stem cell transplantation (allo-SCT) carries a significant risk 
of acute and late post-transplant complications. Improve-
ments in transplantation techniques and supportive care 
have resulted in a reduction of early transplant-related 
mortality (1,2). However, the burden of late complications 
remains high, and two thirds of long-term allo-SCT survi-
vors experience at least one chronic health condition (3). 
These complications occur due to treatment exposures 
before and during allo-SCT, cause substantial mortality, 
and severely impair patients’ functional status and quality 
of life (QOL). This is why today the aim of the treatment is 
not just to cure the primary hematological disease, but to 
facilitate the recovery of the physical and emotional func-
tioning and improve QOL and social reintegration in family 
and work environment.
Health-related QOL is now considered to be one of the rel-
evant treatment outcomes because it provides a broad-
er understanding of the patient’s status beyond simple 
disease-free survival. It is a multi-dimensional construct 
comprised of several related domains including physi-
cal, emotional, social, and role functioning, as well as a 
person’s overall evaluation of his or her well-being and 
ability to function (4,5). Better understanding of QOL in 
long-term survivors is necessary to provide adapted pre-
transplant counseling and recommendations for post-
transplant follow-up.
With a cumulative incidence of 40%-70% and significant 
mortality, chronic GVHD (cGVHD) represents the most im-
portant late complication following allo-SCT (6,7). More-
over, it seems that the incidence of cGVHD in the recent 
years has been increasing, probably due to the fact that 
much older patients undergo allo-SCT, as well as due to 
the increased use of peripheral blood stem cell grafts 
and matched unrelated donors, all known risk factors for 
cGVHD (8). In a series of publications originating from 2005 
National Institutes of Health (NIH) Consensus Conference, 
investigators proposed means to standardize diagnosis, 
scoring, histopathology, biomarkers, response assessment, 
and research in cGVHD (9-14). These criteria were devel-
oped to advance clinical trials and consequently improve 
the management of cGVHD and long-term survivorship af-
ter allo-SCT.
As one of the important treatment outcomes, QOL is in-
creasingly being subjected to the same degree of rigorous 
study as other significant allo-SCT outcomes. Most of the 
studies so far have reported a negative, significant associa-
tion between cGVHD and QOL after allo-SCT (15-20). How-
ever, some of the studies have found no association (21-
25), and this relationship still needs to be elucidated. The 
awareness of the relationship between QOL and cGVHD 
is necessary to further facilitate the prevention and treat-
ment of cGVHD.
The aim of this study was to examine the effect of cGVHD 
on QOL in our cohort of long-term allo-SCT survivors with 
the use of two standard QOL questionnaires; The Short 
Form (36-item) Health Survey (SF-36) and The EORTC Qual-
ity of Life Questionnaire (QLQ C30). Furthermore, we as-
sessed QOL according to cGVHD severity and activity de-
fined by the NIH consensus criteria.
PAtiENtS AND mEthODS
Study design
This cross-sectional study was part of a larger project titled 
“Clinical and Biological Factors Determining Severity and 
Activity of Chronic GVHD after Allogeneic Hematopoietic 
Stem Cell Transplantation” funded by the Unity Through 
Knowledge Fund. This project was conducted at the Uni-
versity Hospital Centre Zagreb, received Ethical approval 
from the same institution as well as from School of Medi-
cine, University of Zagreb. The project included all patients 
referred to hematologist for the evaluation of cGVHD in-
dependently of age or underlying diagnosis. Between July 
2013 and October 2015, total of 76 patients, 47 cGVHD pa-
tients and 29 controls were included in the project.
The inclusion criteria for this study were patients in the 
project who were alive and in complete remission for more 
than one year after allo-SCT. Children were excluded from 
this study. From 60 patients who met the criteria for the 
study, two refused to participate, one due to cGVHD-relat-
ed sight problems and another due to personal reasons. 
Fifty-eight patients who accepted to participate signed an 
informed consent for the study.
Chronic GVhD evaluation
cGVHD was evaluated and scored according to the NIH 
consensus criteria (14). No-cGVHD cohort of patients were 
patients who had never had signs of cGVHD, irrespec-
tively of their acute GVHD status. If they had standard or 
late-acute cGVHD, it had to be resolved and they did 
not receive any immunosuppression at the time of 
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evaluation. For patients with established cGVHD diagnosis, 
additional data regarding the severity and activity of dis-
ease were collected. Disease severity was defined accord-
ing to the global NIH scoring: mild cGVHD involved only 1 
or 2 organs (except lungs, maximum score 1 in all affected 
organs). Moderate cGVHD involved at least 1 organ with 
clinically significant but not major disability (maximum 
score 2) or 3 or more organs with no clinically significant 
functional impairment (maximum score 1 in all affected 
organs). Lung score 1 was classified as moderate. Severe 
cGVHD indicated major impairment caused by cGVHD 
(score 3 in any organ). Lung scores of 2 or 3 were classified 
as severe. Organs scored included the skin, eyes, mouth, 
gastrointestinal tract, liver, lungs, and joint/fascia. The geni-
tal area was scored only in women (14). In order to estab-
lish disease activity we noted a) Clinicians’ impression of 
activity previously defined by Grkovic et al (26) as inactive 
off systemic therapy or topical immunosuppression, inac-
tive on systemic therapy or topical immunosuppression, 
active irrespective of the level of current therapy, or highly 
active irrespective of the level of current therapy, and b) 
intensity of immunosuppression at the time of evaluation 
defined as: none, mild = single agent prednisone <0.5 mg/
kg/d; moderate = prednisone ≥0.5 mg/kg/d and/or any 
single agent/modality; high = 2 or more agents/modali-
ties ± prednisone ≥0.5 mg/kg/d (27).
Quality of life instruments
Patients received two questionnaires at the time of proj-
ect enrollment: SF-36 and EORTC QLQ-C30. SF-36 is a 36-
item self-report questionnaire that assesses patient-re-
ported health and functioning. The instrument examines 
the following domains of QOL: physical functioning, role 
limitations due to physical health, role limitations due to 
emotional problems, energy/fatigue, emotional well-be-
ing, social functioning, pain, and general health (28,29). SF-
36 was translated and validated in Croatian at the School 
of Public Health “Andrija Štampar” for the purposes of the 
health care analysis project and later used in many differ-
ent studies in Croatia (30-32).
The EORTC QLQ-C30 (33) is a cross-culturally validated 
questionnaire of 30 questions, which make 5 multi-item 
functional scales (physical, role, emotional, cognitive, and 
social functioning), and a combined global health status/
QOL scale. Higher scores on these scales indicate better 
functioning (33). Three symptom scales measure fatigue, 
pain, nausea, and vomiting, while 6 single items as-
sess symptoms commonly reported by cancer pa-
tients (dyspnea, sleep disturbances, appetite loss, diarrhea, 
constipation, and financial impact). Higher scores on the 
symptom scales and single items represent greater high-
er impairments. QLQ-C30 version translated and validated 
in Croatian was obtained for this research from the EORTC 
QOL group headquartered in Belgium.
Statistical methods
All analyses were performed using the R package (34). 
Data are presented as median and range. Comparisons of 
global QOL, physical, role, emotional, social functioning, 
and symptom scales between patients with and without 
cGVHD and between patients with moderate and severe 
cGVHD, were evaluated by a non-parametric Mann-Whit-
ney U test. Comparisons between groups with regard to 
activity of cGVHD and level of immunosuppression were 
done with Kruskal-Wallis test. P value <0.050 was consid-
ered significant.
RESuLtS
Study population characteristics
Patients’ and graft characteristics are presented in Table 1. 
The study included 30 male and 28 female patients with 
a median age of 43 years (range 18-71). Most of the pa-
tients (69%) underwent transplantation due to myeloid 
malignancies, 22% due to lymphoid malignancies, and 9% 
due to aplastic anemia. The majority of patients (60%) un-
derwent transplantation after myeloablative conditioning, 
while 40% received reduced-intensity conditioning prior 
to allo-SCT. In 62% of patients the donor was related to 
the patients and in 38% of patients the donor was unre-
lated. Finally, the majority of the patients received periph-
eral blood stem cells (57%), while the rest (43%) received 
the bone marrow. The median follow-up after allo-SCT was 
659 days (range 361-7853). Baseline clinical characteristics 
were similar in patients with and without cGVHD (Table 1).
Chronic GVhD characteristics
cGVHD characteristics are shown in Table 2. 20 patients did 
not meet the NIH criteria for cGVHD diagnosis. In the no 
cGVHD group, 60% of patients previously had had acute 
GVHD but it completely resolved at the time of evaluation 
and they did not receive any immunosuppressive therapy.
cGVHD was diagnosed in 38 patients; mild in 1, moderate 
in 17, and severe in 20 patients, at a median of 298 days 
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after HSCT (range 103-3886). 79% of cGVHD patients pre-
viously had acute GVHD. cGVHD onset was quiescent in 
the majority of patients (47%), progressive in 32%, and it 
occurred de novo in 21% of the patients. At the time of 
the evaluation, cGVHD was classified as classic in 92% of 
the patients, and in 8% of the patients it overlapped with 
acute GVHD. The median number of cGVHD organs in-
volved was 2 (range 1-6), and patients received a median 
of 2 (range 1-4) previous lines of immunosuppressive treat-
ment. According to the clinical impression, 53% of patients 
had active or even highly active cGVHD irrespectively of 
the immunosuppressive treatment, while 34% had inac-
tive cGVHD and were off immunosuppressive therapy. The 
remaining 13% of the patients had inactive cGVHD but still 
received immunosuppressive treatment. The majority of 
patients (53%) received no immunosuppressive treatment 
at the time of enrolment, 29% were treated with moderate 
immunosuppression, while 18% of patients received high-
dose immunosuppressive therapy.
Quality of life
In the analysis of QOL of all patients, we found that female 
patients, patients older than 50 years, and patients who 
fulfilled the questionnaires less than two years after allo-
SCT had lower QOL scores than men, younger patients, 
or patients with longer follow up, although this difference 
did not reach statistical significance (data not shown). On 
tABLE 1. Demographic characteristics of the study population, N (%)
Characteristic
Patients without 
cGVhD* (n = 20)
Patients with
cGVhD (n = 38)
All patients
(n = 58)
P 
(mann-Whitney)
Patient age median (range)  42 (18-71)  44 (21-56)  43 (18-71) 0.312
Sex
male  10 (50)  19 (50)  30 (52)
female  10 (50)  19 (50)  28 (48) 1.00
Diagnosis
myeloid malignancies  14 (70)  26 (68)  40 (69)
lymphoid malignancies   5 (25)   8 (21)  13 (22)
aplastic anemia   1 (5)   4 (11)   5 (9) 0.832
Stem cell source
bone marrow   9 (45)  16 (42)  25 (43)
peripheral blood stem cells  11 (55)  22 (58)  33 (57) 1.00
Donor type
matched related donor  11 (55)  25 (66)  36 (62)
matched unrelated donor   9 (45)  13 (44)  22 (38) 0.583
Conditioning regimen
myeloablative  12 (60)  23 (60)  35 (60)
reduced-intensity   8 (40)  15 (40)  23 (40) 1.00
Days from transplant to enrolment, median (range) 713 (361-5518) 606 (367-7853) 659 (361-7853) 0.472
*cGVHD – chronic graft vs-host disease.
tABLE 2. Characteristics of chronic graft-vs-host disease 
(cGVhD) patients
Characteristic N (%)
cGVhD
mild   1 (2)
moderate  17 (45)
severe  20 (53)
cGVHD days after transplantation
median (range)
298 
(103-3886)
cGVhD onset
de novo   8 (21)
progressive  12 (32)
quiescent  18 (47)
cGVhD classification time of evaluation
classic  35 (92)
overlap   3 (8)
cGVhD organs involved
median (range)   2 (1-6)
cGVhD lines of immunosuppression
median (range)   2 (1-4)
Clinician’s impression of cGVhD activity
inactive of systemic or topical immunosuppression  13 (34)
inactive on systemic or topical immunosuppression   5 (13)
active irrespective of immunosuppression  17 (45)
highly active irrespective of immunosuppression   3 (8)
intensity of immunosuppression at time of 
evaluation
none  20 (53)
moderate  11 (29)
high   7 (18)
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the other hand, compared to patients without cGVHD, pa-
tients with cGVHD had significantly lower mean scores 
on all QOL subscales of the SF 36 questionnaire. Namely, 
cGVHD patients had significantly lower scores on physical 
functioning subscale, more role limitations due to physi-
cal and emotional functioning, less energy, worse emo-
tional well-being and social functioning, more pain, and 
worse general health (P < 0.050 for all comparisons) (Table 
3). cGVHD patients also had significantly lower QOL scores 
on QLQ C30 global health status and on most functional 
subscales (physical, role, emotional, and social) (P < 0.050 
for all subscales). The difference was not significant only 
for cognitive functioning (Table 4). Moreover, on QLQ C30 
symptom scales, cGVHD patients reported significant-
ly more pain, dyspnea, and sleeping disorders (P = 0.010, 
P = 0.043, and P = 0.043, respectively) (Table 4). There was 
no difference in the scores for other symptoms: fatigue, 
nausea and vomiting, constipation, diarrhea, appetite loss, 
and financial difficulties. When we evaluated the sever-
ity of the cGVHD, patients with severe cGVHD had lower 
QOL scores than patients with mild/moderate cGVHD on 
both SF-36 (Figure 1) and QLQ C30 questionnaires (Figure 
2). This difference was greatest in physical functioning and 
role limitations due to physical health on SF-36, as well as 
in global status and social functioning scores on QLQ C30, 
but it did not reach statistical difference. According to cli-
nician’s impression, we further divided the patients with 
cGVHD into those with active disease (active or highly ac-
tive irrespectively of immunosuppressive treatment) and 
inactive (irrespectively of immunosuppressive therapy). Pa-
tients with active cGVHD had consistently lower QOL SF-
36 scores, ie, significantly lower physical functioning, role 
limitations due to physical health, and social functioning, 
as well as less energy/more fatigue (P = 0.0007, P = 0.026, 
tABLE 3. mean scores in the Short Form (36) health Survey (SF-36) questionnaire subscales in patients with and without chronic 
graft-vs-host disease (cGVhD)
SF-36 mean (standard deviation)
Patients without cGVhD 
(n = 20)
Patients with cGVhD 
(n = 38)
P 
(mann-Whitney)
Physical functioning 72.86 (24.06) 53.84 (26.27) 0.007
Role limitations due to physical health 63.10 (42.29) 34.46 (40.97) 0.025
Role limitations due to emotional problems 84.13 (32.69) 45.94 (44.69) 0.004
Energy/Fatigue 66.19 (18.30) 49.39 (19.04) 0.005
Emotional well-being 73.86 (13.71) 61.00 (19.23) 0.017
Social functioning 82.14 (19.19) 56.76 (26.29) 0.0004
Pain 78.93 (22.84) 59.53 (28.30) 0.008
General health 62.20 (21.42) 43.26 (19.62) 0.018
tABLE 4. mean scores in the EORtC Quality of Life Questionnaire C30 (QLQ C30) questionnaire subscales in patients with and with-
out chronic graft-vs-host disease (cGVhD)
QLQ C30 mean (standard deviation)
Patients without cGVhD 
(n = 20)
Patients with cGVhD 
(n = 38)
P 
(mann-Whitney)
Global health status 75.00 (21.25) 52.70 (25.16) 0.001
Functional scales
physical functioning 79.05 (20.36) 64.68 (24.09) 0.022
role functioning 80.16 (29.16) 54.50 (33.94) 0.005
emotional functioning 78.32 (21.79) 62.16 (25.05) 0.017
cognitive functioning 85.71 (12.12) 70.72 (28.17) 0.084
social functioning 79.37 (18.93) 49.55 (32.98) 0.001
Symptom scale
fatigue 28.78 (20.53) 42.26 (26.92) 0.063
nausea and vomiting 4.76 (10.73) 10.36 (19.39) 0.312
pain 17.46 (25.54) 42.72 (35.69) 0.010
dyspnea 20.63 (24.67) 36.94 (28.09) 0.043
insomnia 22.22 (26.53) 38.74 (27.79) 0.043
appetite loss 12.70 (24.67) 26.13 (34.37) 0.190
constipation 4.76 (11.95) 13.51 (24.16) 0.356
financial disturbances 30.16 (31.46) 46.85 (39.64) 0.139
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P = 0.017, and P = 0.014, respectively) (Table 5). Patients 
with active cGVHD also had significantly lower QLQ C30 
scores, ie, worse physical and role functioning, as well as 
global health, and social functioning (P = 0.015, P = 0.011, 
P = 0.029, and P = 0.009, respectively (Table 6). Finally we 
examined QOL in patients with cGVHD according to the 
level of immunosuppressive treatment at the time of eval-
uation. Patients with high and moderate intensity of im-
munosuppression had significantly lower scores on physi-
cal functioning subscale (P = 0.044) and role limitations 
due to physical health (P = 0.031) of SF-36 (Table 5) and on 
general health subscale (P = 0.039), as well as more pain on 
the symptom scales (P = 0.033) of QLQ C30 (Table 6).
DiSCuSSiON
In this study we investigated the ability of standard QOL 
questionnaires, SF-36 and QLQ C30, to evaluate QOL in pa-
tients with cGVHD graded according to NIH consensus cri-
teria. Previous reports have identified cGVHD as the most 
important predictor of adverse long-term late effects and 
poor overall health after allo-SCT (3,35,36). Moreover, pre-
vious studies have mostly shown the adverse impact of 
cGVHD on health-related QOL (15-20). The limitations in 
assessing the results of these reports are related to their 
heterogeneous nature. Also, most of these studies evaluat-
ed QOL with regard to cGVHD without reviewing its sever-
ity or by grading the severity according to the old scoring 
system developed in the 1980s (37). Only one study ex-
amined the relationship between cGVHD severity defined 
by the new NIH Consensus criteria and QOL, and this was 
done with two standard QOL questionnaires – SF-36 and 
Functional Assessment of Cancer Therapy-Bone Marrow 
Transplant (FACT-BMT). This study found cGVHD severity to 
be independently associated with QOL in both question-
naires, adjusted for age (38).
FiGuRE 1. mean scores in the Short Form (36) health Survey 
(SF-36) questionnaire subscales in patients with mild/moder-
ate and severe chronic graft-vs-host disease (cGVhD).
FiGuRE 2. mean scores in the EORtC Quality of Life Question-
naire C30 (QLQ C30) questionnaire functional subscales in 
patients with mild/moderate and severe chronic graft-vs-host 
disease (cGVhD).
tABLE 5. mean scores in the Short Form (36) health Survey (SF-36) questionnaire subscales according to chronic graft-vs-host dis-
ease (cGVhD) activity and intensity of immunosuppression
SF-36 mean
Patients with 
inactive cGVhD
Patients with active 
or highly active
P (mann- 
Whitney
intensity of immunosuppression
P (Kruskal-
(standard deviation) (n = 18) cGVhD (n = 20) test) no (n = 20) moderate (n = 11) high (n = 7) Wallis test)
Physical functioning 70.40 (21.25) 41.0 (23.65) 0.007 62.25 (24.62) 59.36 (21.69) 30.71 (27.14) 0.044
Role limitations due to 
physical health
52.78 (41.91) 21.25 (36.52) 0.026 51.19 (42.19) 29.55 (40.02) 3.57 (9.45) 0.031
Role limitations due to 
emotional problems
59.25 (43.62) 36.66 (44.46) 0.161 49.20 (46.69) 63.64 (43.35) 23.80 (37.09) 0.195
Energy/fatigue 59.41 (18.53) 42.90 (18.20) 0.017 54.0 (22.98) 47.27 (15.55) 44.0 (14.73) 0.349
Emotional well-being 73.86 (13.71) 61.00 (19.23) 0.411 62.20 (22.04) 63.64 (16.92) 55.43 (13.75) 0.637
Social functioning 69.44 (21.53) 47.50 (34.28) 0.014 62.50 (25.92) 59.09 (22.42) 41.07 (31.22) 0.266
Pain 63.19 (19.68) 57.25 (34.28) 0.650 60.95 (25.76) 70.22 (28.01) 37.50 (26.38) 0.059
General health 49.04 (20.14) 39.44 (18.63) 0.279 48.69 (23.34) 40.34 (11.01) 35.0 (18.71) 0.428
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In our study, older age, female sex, and short follow-up 
were not found to be predictive factors of worse QOL, as 
it was shown before (18,39,40). However, we confirmed 
that patients with cGVHD reported significantly lower 
QOL than control patients without cGVHD on all func-
tional scales and general well-being evaluated by SF-36. 
Moreover, QOL of patients without cGVHD was compa-
rable to normative data of the Croatian population mea-
sured with SF-36 (30). To the best of our knowledge, this 
is the first report to evaluate QOL with EORTC QLQ C30 
questionnaire in patients with cGVHD defined by the NIH 
Consensus criteria. Compared with previous findings on 
QLQ C30 in allo-SCT, which show improvement of QOL 
scores over time (41), our patients without cGVHD had 
similar mean QOL scores as patients more than 3 years 
after allo-SCT, while cGVHD patients had scores compa-
rable to QOL of patients at discharge from the hospital 
after allo-SCT. In our study population the differences 
between cGVHD patients and no-cGVHD controls were 
most evident in global health status, and physical and so-
cial well-being. These results indicate that C30 adds more 
information on social well-being of cGVHD patients and 
should be used as a valuable instrument of evaluation in 
the social domains of QOL.
When we compared patients with moderate cGVHD to 
patients with severe cGVHD, patients with moder-
ate cGVHD had higher QOL subscale scores, but the dif-
ference was not significant, presumably due to the small 
number of patients. For the same reason, we could not 
compare the difference in QOL between patients with 
mild and moderate cGVHD, as we had only one patient 
with mild cGVHD. This is probably due to the referral pat-
tern of these patients to our institution and some of the 
mild cGVHD have probably stayed undetected. Addition-
ally, we evaluated QOL in cGVHD patients according to 
the cGVHD activity and intensity of immunosuppressive 
treatment. As patients with inactive cGVHD and patients 
without immunosuppressive therapy had better QOL 
scores, our results confirmed that the resolution of cGVHD 
and discontinuation of immunosuppressive treatment re-
duced QOL impairment in cGVHD patients.
Our study has a number of limitations. We used a group of 
patients from a single institution, and patients were includ-
ed in the study at different time points after allo-SCT us-
ing heterogeneous transplant regimens. However, the pa-
tients were also part of a prospective observational study 
and therefore they had to meet the same inclusion criteria 
and were evaluated in a homogenous manner. Neverthe-
less, our ability to draw conclusions in a heterogeneous 
patient group supports the use of both SF-36 and C30 as 
valuable tools in the evaluation of the effect of GVHD on 
QOL in different clinical settings.
tABLE 6. mean scores in the EORtC Quality of Life Questionnaire C30 (QLQ C30) questionnaire subscales according to chronic graft-
vs-host disease (cGVhD) activity and intensity of immunosuppression
QLQ C30 mean 
(standard deviation)
Patients with  
inactive cGVhD 
(n = 18)
Patients with active 
or highly active 
cGVhD (n = 20)
P (mann- 
Whitney 
test)
intensity of immunosuppression P (Kruskal- 
Wallis test)no (n = 20) moderate (n = 11) high (n = 7)
Global health status 63.42 (22.89) 44.58 (24.52) 0.015 59.12 (26.99) 55.30 (20.16) 33.33 (15.96) 0.039
Functional scales
physical functioning 75.0 (20.90) 56.50 (23.73) 0.011 72.06 (21.89) 63.03 (17.98) 49.52 (31.24) 0.096
role functioning 68.52 (32.28) 44.17 (32.57) 0.029 61.91 (33.81) 59.09 (33.64) 33.33 (28.87) 0.142
emotional functioning 66.20 (28.51) 60.0 (22.06) 0.427 64.29 (23.88) 62.12 (33.41) 55.95 (14.99) 0.583
cognitive functioning 72.22 (24.15) 70.0 (27.36) 0.726 73.02 (26.60) 71.21 (31.70) 64.29 (26.22) 0.668
social functioning 65.74 (24.41) 37.50 (31.93) 0.009 61.91 (31.69) 45.46 (28.96) 28.57 (34.31) 0.070
Symptom scale
fatigue 33.26 (20.16) 49.92 (29.59) 0.057 40.65 (23.39) 36.30 (27.69) 58.67 (31.18) 0.169
nausea and vomiting 3.70 (7.13) 15.83 (24.47) 0.121  9.52 (22.71)  6.06 (11.24) 19.05 (14.99) 0.152
pain 35.19 (31.77) 47.50 (39.09) 0.349 38.09 (35.80) 30.30 (33.18) 73.81 (21.21) 0.033
dyspnea 31.48 (24.18) 40.0 (31.72) 0474 39.68 (29.09) 27.27 (25.03) 42.86 (31.71) 0.492
insomnia 38.89 (26.19) 40.0 (29.81) 0.953 42.86 (30.08) 27.27 (20.10) 52.38 (26.23) 0.133
appetite loss 16.67 (30.78) 33.33 (35.87) 0.147 25.39 (36.37) 21.21 (26.97) 33.33 (38.49) 0.814
constipation 18.52 (28.52)  8.33 (18.33) 0.396 14.29 (24.88)  9.09 (21.56) 14.29 (9.91) 0.882
diarrhea  5.56 (12.78) 10.53 (24.97) 0.785  7.94 (14.55)  3.03 (10.05) 16.67 (40.83) 0.805
financial disturbances 46.29 (41.44) 46.67 (38.08) 0.971 34.92 (37.23) 57.58 (36.79) 57.14 (46.0) 0.234
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Today, there is a widespread interest in possible interven-
tions to improve QOL in long-term allo-SCT survivors. Be-
havioral interventions, such as supervised exercise during 
hospitalization for allo-SCT, have been shown to result in 
better long-term physical well-being, decreased fatigue, 
and emotional distraction (42-44). Furthermore, psychoso-
cial interventions, such as stress management and coping 
skills training reduced pain in allo-SCT survivors (45,46). Fi-
nally, a dedicated GVHD clinic with an active involvement 
of specialists interested in GVHD can also improve QOL of 
patients with cGVHD (47).
In conclusion, we confirmed QOL as a valid measure of 
cGVHD defined and staged by NIH consensus criteria. The 
results suggest that SF-36 is a useful questionnaire in the 
evaluation of cGVHD effect on QOL, particularly in the 
physical domains, while QLQ C30 provides additional value, 
especially in social domains. Future studies are needed to 
continue longitudinal QOL assessment by the same means 
in order to improve the outcomes of cGVHD patients.
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